Novo Nordisk STEP Young meets primary endpoint; two heart studies halted
Novo Nordisk said STEP Young Phase 3 met its primary endpoint: 40.4% of children aged 6 to under 12 were off obesity after 68 weeks on semaglutide plus lifestyle versus 0% on placebo. Two heart-disease studies were stopped.
4% of children aged 6 to under 12 treated with semaglutide plus lifestyle modification were no longer classified as having obesity after 68 weeks, versus 0% on placebo. · The 165-patient trial met its primary endpoint, with safety and tolerability consistent with previous semaglutide trials and no new concerns identified for growth or pubertal development. · Separately, Novo Nordisk has stopped two additional studies involving an experimental heart-disease drug, marking another setback for the program.